Stockscreener 앱 받기
1.17
6.40%
-0.08
시간 외 거래:
1.17
전일 마감가:
$1.25
열려 있는:
$1.25
하루 거래량:
9,247
Relative Volume:
0.48
시가총액:
$3.14M
수익:
-
순이익/손실:
$-4.69M
주가수익비율:
-0.5021
EPS:
-2.33
순현금흐름:
$-3.81M
1주 성능:
-11.36%
1개월 성능:
-9.02%
6개월 성능:
-47.53%
1년 성능:
-49.79%
1일 변동 폭
$1.155
$1.25
1주일 범위
$1.155
$1.41
52주 변동 폭
$1.02
$3.50
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
명칭
Lixte Biotechnology Holdings Inc
전화
310 203 2902
주소
248 ROUTE 25A, EAST SETAUKET
LIXT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
1.17 | 3.54M | 0 | -4.69M | -3.81M | -2.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Lixte Biotechnology Holdings Inc 주식(LIXT)의 최신 뉴스
Lixte Biotechnology Converts Preferred Stock to Common - TipRanks
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. SEC 10-Q Report - TradingView
Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com India
Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 44.0% in March - Defense World
SEC Form 424B4 filed by Lixte Biotechnology Holdings Inc. - Quantisnow
LIXTE Launches New Study to Determine if Certain - GlobeNewswire
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - GlobeNewswire
Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults - Stock Titan
LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials - Nasdaq
LIXTE Biotechnology Provides Update On Progress with - GlobeNewswire
Major Breakthrough: LIXTE's Cancer Drug Shows Promise in New GSK, Roche Clinical Trials - Stock Titan
Lixte Biotechnology Holdings Inc. (LIXT) reports earnings - Quartz
Lixte Biotechnology revises sarcoma study agreement By Investing.com - Investing.com Australia
Lixte Biotechnology revises sarcoma study agreement - Investing.com
Lixte Biotech ends sales agreement, explores funding options By Investing.com - Investing.com South Africa
Lixte Biotechnology terminates sales agreement with Wallachbeth Capital -March 11, 2025 at 10:35 am EDT - Marketscreener.com
Lixte Biotech ends sales agreement, explores funding options - Investing.com
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form - GlobeNewswire
New Research Reveals Key Mechanism Behind LIXT's Cancer Drug LB-100 - StockTitan
LIXTE Adds Northwestern University’s Lurie Cancer Center as - GlobeNewswire
LIXTE Biotechnology Teams Up with Lurie Cancer Center to Initiate Clinical Trial of LB-100 and GSK’s Dostarlimab for Ovarian Clear Cell Cancer - Nasdaq
Can LIXTE's Cancer Drug Breakthrough Succeed Where Others Failed? Northwestern Joins Trial - StockTitan
Lixte Biotechnology faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Lixte Biotechnology faces Nasdaq delisting over equity shortfall - Investing.com India
Lixte Biotechnology Holdings, Inc. Announces Successful Closure of $1.05 Million Offering - Defense World
Lixte Biotechnology announces closing of $1.05M registered direct offering - Yahoo Finance
LIXTE Biotechnology Announces Closing of $1.05 Million - GlobeNewswire
Lixte Biotechnology Closes $1.1 Million Direct Offering -February 13, 2025 at 11:06 am EST - Marketscreener.com
LIXTE Biotechnology Holdings, Inc. Completes Registered Direct Offering and Private Placement Raising Approximately $1.05 Million - Nasdaq
LIXTE Secures Critical $1.05M Funding: Strategic Move Unlocks Next Growth Phase - StockTitan
LIXTE Biotechnology announces $1.05M registered direct offering; shares fall - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
LIXTE Biotech (LIXT) Secures Fresh Capital: Strategic $1.05M Direct Offering Includes Warrant Sweetener - StockTitan
Lixte Biotechnology Holdings Inc Inc. (LIXT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - GlobeNewswire
Lixte Biotechnology enters agreement for at-the-market stock sale - Investing.com
Lixte Biotechnology Holdings, Inc. Enters into At-the-Market Sales Agreement with WallachBeth Capital, LLC - Defense World
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update - Defense World
Lixte Biotechnology Holdings, Inc. Vice President and COO Resigns - Defense World
Lixte Biotechnology announces executive departure By Investing.com - Investing.com Nigeria
Lixte Biotechnology announces executive departure - Investing.com
US Penny Stocks To Watch In December 2024 - Simply Wall St
Lixte Biotechnology Holdings Inc (LIXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):